Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 16 | 2022 | 638 | 3.510 |
Why?
|
| Magnetic Resonance Imaging | 23 | 2022 | 1328 | 2.940 |
Why?
|
| Oxygen | 15 | 2015 | 142 | 2.810 |
Why?
|
| Phosphatidylserines | 7 | 2019 | 8 | 2.760 |
Why?
|
| Glioma | 6 | 2016 | 136 | 1.790 |
Why?
|
| Nanoparticles | 4 | 2019 | 52 | 1.730 |
Why?
|
| Prostatic Neoplasms | 17 | 2015 | 471 | 1.670 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 765 | 1.610 |
Why?
|
| Cell Line, Tumor | 21 | 2022 | 726 | 1.580 |
Why?
|
| Contrast Media | 7 | 2022 | 138 | 1.550 |
Why?
|
| Molecular Imaging | 5 | 2017 | 20 | 1.530 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 412 | 1.330 |
Why?
|
| Animals | 45 | 2022 | 7541 | 1.300 |
Why?
|
| Liposomes | 4 | 2019 | 27 | 1.290 |
Why?
|
| Mice | 20 | 2022 | 2484 | 1.090 |
Why?
|
| Mice, Nude | 10 | 2022 | 291 | 0.970 |
Why?
|
| Neoplasm Transplantation | 8 | 2016 | 73 | 0.950 |
Why?
|
| Stilbenes | 3 | 2011 | 23 | 0.940 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2011 | 37 | 0.920 |
Why?
|
| Neoplasms, Experimental | 5 | 2018 | 29 | 0.840 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2014 | 29 | 0.840 |
Why?
|
| Cell Hypoxia | 9 | 2015 | 41 | 0.840 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2022 | 4 | 0.820 |
Why?
|
| Rats | 23 | 2016 | 1595 | 0.740 |
Why?
|
| Oximetry | 9 | 2015 | 31 | 0.730 |
Why?
|
| Nucleotides, Cyclic | 1 | 2019 | 1 | 0.700 |
Why?
|
| Antigen-Presenting Cells | 1 | 2019 | 6 | 0.700 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 11 | 0.690 |
Why?
|
| Mice, Inbred BALB C | 6 | 2019 | 167 | 0.680 |
Why?
|
| Radiotherapy | 1 | 2019 | 82 | 0.660 |
Why?
|
| Immunotherapy | 1 | 2019 | 81 | 0.660 |
Why?
|
| Transplantation, Heterologous | 4 | 2015 | 122 | 0.660 |
Why?
|
| Carbon Dioxide | 5 | 2015 | 38 | 0.620 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2015 | 83 | 0.620 |
Why?
|
| Membrane Proteins | 1 | 2019 | 256 | 0.610 |
Why?
|
| Diagnostic Imaging | 3 | 2013 | 94 | 0.610 |
Why?
|
| Glioblastoma | 5 | 2022 | 156 | 0.610 |
Why?
|
| Lung | 1 | 2019 | 249 | 0.600 |
Why?
|
| Luminescent Measurements | 2 | 2018 | 16 | 0.550 |
Why?
|
| Neovascularization, Pathologic | 2 | 2014 | 82 | 0.530 |
Why?
|
| Arsenicals | 1 | 2015 | 12 | 0.510 |
Why?
|
| Oxides | 1 | 2015 | 16 | 0.510 |
Why?
|
| Manganese | 1 | 2015 | 10 | 0.510 |
Why?
|
| Humans | 29 | 2022 | 32005 | 0.480 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 104 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 104 | 0.430 |
Why?
|
| Blood Vessels | 1 | 2013 | 48 | 0.430 |
Why?
|
| Endothelial Cells | 4 | 2016 | 189 | 0.420 |
Why?
|
| Blood-Brain Barrier | 3 | 2017 | 48 | 0.390 |
Why?
|
| Ultrasonography | 1 | 2014 | 379 | 0.390 |
Why?
|
| Hemoglobins | 1 | 2011 | 49 | 0.380 |
Why?
|
| Deoxyglucose | 1 | 2009 | 16 | 0.350 |
Why?
|
| Pituitary Neoplasms | 2 | 2000 | 17 | 0.350 |
Why?
|
| Fluorocarbons | 4 | 2004 | 21 | 0.340 |
Why?
|
| Fluorine Radioisotopes | 1 | 2009 | 19 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 458 | 0.330 |
Why?
|
| Female | 16 | 2019 | 19959 | 0.330 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2013 | 10 | 0.320 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 582 | 0.320 |
Why?
|
| Immunohistochemistry | 5 | 2013 | 538 | 0.310 |
Why?
|
| Echo-Planar Imaging | 3 | 2007 | 15 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 210 | 0.300 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 762 | 0.300 |
Why?
|
| Administration, Inhalation | 2 | 2019 | 54 | 0.300 |
Why?
|
| Neoplasms | 3 | 2018 | 726 | 0.280 |
Why?
|
| Radiation Tolerance | 3 | 2016 | 24 | 0.280 |
Why?
|
| Radiopharmaceuticals | 4 | 2018 | 93 | 0.280 |
Why?
|
| Disease Models, Animal | 5 | 2015 | 1022 | 0.260 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2005 | 14 | 0.260 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 36 | 0.250 |
Why?
|
| Cattle | 2 | 2016 | 103 | 0.250 |
Why?
|
| Male | 22 | 2016 | 19165 | 0.240 |
Why?
|
| Rats, Inbred F344 | 3 | 2011 | 133 | 0.240 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 608 | 0.230 |
Why?
|
| Signal Transduction | 3 | 2017 | 682 | 0.230 |
Why?
|
| Respiration | 1 | 2003 | 27 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 115 | 0.220 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2015 | 53 | 0.220 |
Why?
|
| Necrosis | 3 | 2011 | 53 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 261 | 0.200 |
Why?
|
| Fluorine | 5 | 2005 | 5 | 0.200 |
Why?
|
| RNA | 1 | 2022 | 92 | 0.190 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 767 | 0.190 |
Why?
|
| Nitroimidazoles | 2 | 2015 | 4 | 0.190 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2000 | 4 | 0.180 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 560 | 0.180 |
Why?
|
| Adenoma | 1 | 2000 | 35 | 0.180 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3306 | 0.180 |
Why?
|
| Partial Pressure | 3 | 2005 | 6 | 0.180 |
Why?
|
| Phantoms, Imaging | 3 | 2018 | 60 | 0.180 |
Why?
|
| Oxygen Consumption | 3 | 2007 | 154 | 0.170 |
Why?
|
| Interferon Type I | 1 | 2019 | 11 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 246 | 0.170 |
Why?
|
| Dendritic Cells | 1 | 2019 | 59 | 0.170 |
Why?
|
| Luminescence | 2 | 2009 | 3 | 0.170 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1999 | 35 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2009 | 21 | 0.160 |
Why?
|
| Ki-67 Antigen | 1 | 1999 | 30 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 1999 | 55 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1999 | 71 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 101 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 308 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 166 | 0.150 |
Why?
|
| Macrophages | 1 | 2019 | 191 | 0.150 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2017 | 14 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 35 | 0.150 |
Why?
|
| Endothelium, Vascular | 3 | 2011 | 156 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 148 | 0.140 |
Why?
|
| Astrocytoma | 2 | 2008 | 29 | 0.140 |
Why?
|
| Ferric Compounds | 1 | 2016 | 15 | 0.140 |
Why?
|
| Photons | 1 | 2016 | 7 | 0.140 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 163 | 0.130 |
Why?
|
| Tissue Distribution | 2 | 2013 | 61 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2016 | 84 | 0.130 |
Why?
|
| Aorta | 1 | 2016 | 126 | 0.130 |
Why?
|
| Gallium Radioisotopes | 1 | 2015 | 2 | 0.130 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2015 | 3 | 0.130 |
Why?
|
| Hyperoxia | 1 | 2015 | 3 | 0.130 |
Why?
|
| Permeability | 1 | 2014 | 9 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 134 | 0.120 |
Why?
|
| Molecular Probes | 1 | 2014 | 16 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 1 | 2014 | 19 | 0.120 |
Why?
|
| Radiography | 1 | 2015 | 376 | 0.120 |
Why?
|
| Nanocomposites | 1 | 2013 | 5 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 70 | 0.110 |
Why?
|
| Apoptosis | 3 | 2019 | 360 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 170 | 0.110 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2013 | 3 | 0.110 |
Why?
|
| Oxyhemoglobins | 2 | 2011 | 7 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2003 | 15 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2014 | 135 | 0.110 |
Why?
|
| Time Factors | 2 | 2011 | 2149 | 0.110 |
Why?
|
| Thalidomide | 2 | 2019 | 31 | 0.110 |
Why?
|
| NF-kappa B | 2 | 2009 | 81 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 23 | 0.100 |
Why?
|
| Tubulin Modulators | 1 | 2011 | 10 | 0.100 |
Why?
|
| Microvessels | 1 | 2011 | 25 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 62 | 0.090 |
Why?
|
| Models, Biological | 2 | 2010 | 392 | 0.090 |
Why?
|
| Perfusion | 1 | 2009 | 73 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2019 | 604 | 0.090 |
Why?
|
| Protons | 1 | 2009 | 23 | 0.090 |
Why?
|
| Genes, Neurofibromatosis 1 | 2 | 2008 | 3 | 0.080 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2009 | 5 | 0.080 |
Why?
|
| Genes, p53 | 2 | 2008 | 23 | 0.080 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2009 | 5 | 0.080 |
Why?
|
| Ligands | 2 | 2022 | 81 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 112 | 0.080 |
Why?
|
| Prognosis | 3 | 2009 | 1497 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 82 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 68 | 0.080 |
Why?
|
| Glucose | 1 | 2009 | 174 | 0.080 |
Why?
|
| Loss of Heterozygosity | 1 | 2008 | 20 | 0.080 |
Why?
|
| Arsenic | 1 | 2008 | 3 | 0.080 |
Why?
|
| Radioisotopes | 1 | 2008 | 5 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2008 | 40 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2007 | 9 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2022 | 189 | 0.070 |
Why?
|
| Electrodes | 2 | 2003 | 17 | 0.070 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 52 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 38 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2005 | 86 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2005 | 93 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 112 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 16 | 0.060 |
Why?
|
| Drug Administration Routes | 1 | 2004 | 12 | 0.060 |
Why?
|
| Algorithms | 2 | 2004 | 495 | 0.060 |
Why?
|
| Oncogenes | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cell Survival | 2 | 2017 | 284 | 0.050 |
Why?
|
| Radiobiology | 1 | 2002 | 5 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2002 | 22 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 767 | 0.050 |
Why?
|
| Adult | 4 | 2010 | 9345 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 30 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1999 | 9 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 1999 | 45 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 1999 | 9 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 55 | 0.040 |
Why?
|
| Mutation | 2 | 2015 | 489 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 20 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 1999 | 190 | 0.040 |
Why?
|
| Aged | 3 | 2000 | 10301 | 0.040 |
Why?
|
| Middle Aged | 3 | 2000 | 11817 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2018 | 508 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 81 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2015 | 1 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2018 | 180 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 71 | 0.030 |
Why?
|
| Biological Transport | 1 | 2015 | 69 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 61 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 407 | 0.030 |
Why?
|
| Stem Cells | 2 | 2008 | 313 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2016 | 469 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2013 | 108 | 0.030 |
Why?
|
| Disease Progression | 2 | 2008 | 594 | 0.030 |
Why?
|
| Tubulin | 1 | 2011 | 12 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2011 | 14 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2011 | 24 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2011 | 59 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 88 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 108 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Adolescent | 1 | 1999 | 3539 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 26 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2009 | 26 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 198 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 833 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 114 | 0.020 |
Why?
|
| DNA Damage | 1 | 2009 | 98 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2008 | 6 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2008 | 4 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 208 | 0.020 |
Why?
|
| Radioimmunodetection | 1 | 2008 | 3 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 264 | 0.020 |
Why?
|
| Cell Movement | 1 | 2008 | 169 | 0.020 |
Why?
|
| Penetrance | 1 | 2005 | 4 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2005 | 48 | 0.020 |
Why?
|
| Neurons | 1 | 2008 | 410 | 0.010 |
Why?
|
| Ploidies | 1 | 1999 | 7 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1999 | 77 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1999 | 108 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 876 | 0.010 |
Why?
|